Bartlett DW, Davis ME (2008). Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnology & Bioengineering 99(4):975-85.
Bartlett DW, Su H, Hildebrandt IJ, Weber WA, and Davis ME (2007). Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proceedings of the National Academy of Sciences 104(39):15549-54. Related link: http://www.pnas.org/papbyrecent.shtml
Mullin R (2007). Delivering RNA: Case Study #2: Two firms partner to make the active ingredient and a delivery component of a cancer therapy. Chemical & Engineering News 85(14):22-3.
Heidel JD, Yu Z, Liu JY-C, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, and Davis ME (2007). Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing RRM2 siRNA. Proceedings of the National Academy of Sciences 104(14):5715-21. Related link: http://www.pnas.org/papbyrecent.shtml
Heidel JD, Liu JY-C, Yen Y, Zhou B, Heale BSE, Rossi JJ, Bartlett DW, and Davis ME (2007). Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clinical Cancer Research 13(7):2207-15.
Bartlett DW and Davis ME (2007). Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjugate Chemistry 18(2):456-68.
Bartlett DW and Davis ME (2007). Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnology and Bioengineering 97(4):909-21.
Heidel JD (2006). Linear cyclodextrin-containing polymers and their use as delivery agents. Expert Opinion on Drug Delivery 3(5):641-6.
Mishra S, Heidel JD, Webster P, and Davis ME (2006). Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes. Journal of Controlled Release 116:179-91
Bartlett DW and Davis ME (2006). Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Research 34(1):322-33.
Rose SD, Kim D-H, Amarzguioui M, Heidel JD, Collingwood MA, Davis ME, Rossi JJ, and Behlke MA (2005). Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Research 33:4140-56.
Heidel JD, Hu S, Liu XF, Triche TJ, and Davis ME (2004). Lack of interferon response in animals to naked siRNAs. Nature Biotechnology 22(12):1579-82.
Davis ME and Brewster ME (2004). Cyclodextrin-based pharmaceutics: past, present and future. Nature Reviews. Drug Discovery 3(12):1023-35.
Davis ME, Pun SH, Bellocq NC, Reineke TM, Popielarski SR, Mishra S, and Heidel JD (2004).
Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Current Medicinal Chemistry 11(2):179-97.
2007
9th US-Japan Drug Delivery Symposium: Targeted siRNA-containing formulations for clinical, systemic application. Heidel JD. December 18, 2007.
3rd Annual Meeting of the Oligonucleotide Therapeutics Society, Berlin, Germany: Preclinical development of targeted nanoparticles for systemic delivery of siRNA. Heidel JD. October 6, 2007.
Charles River Laboratories Preclinical Services’ 2007 Annual Symposium on Biotechnology-Derived Therapeutics: Perspectives on Nonclinical Development, Incline Village, NV: Nanoparticle formulations for systemic delivery of siRNA. Heidel JD. September 11, 2007.
TIDES Conference, Las Vegas, CA: The landscape of delivery technologies for oligonucleotides: Where are we today, prospects for the future. Davis ME. May 21, 2007.
TIDES Conference, Las Vegas, CA: Development of siRNA-containing, targeted nanoparticle formulations. Heidel JD. May 21, 2007.
American Association for Cancer Research (AACR) Annual Meeting, Los Angeles, CA: Development and in vivo tolerability testing of a therapeutic formulation containing siRNA against the M2 subunit of ribonucleotide reductase in mice and monkeys. Heidel JD, Liu JY-C, Yu Z, Liang Y, Rele SM, Yen Y, and Davis ME. April 14-18, 2007.
American Association for Cancer Research (AACR) Annual Meeting, Los Angeles, CA: Kinetics of the biodistribution and tumor localization of targeted, siRNA nanoparticles after systemic delivery in mice using PET imaging. Bartlett DW, Su H, Hildebrandt I, Weber WA, and Davis ME. April 14-18, 2007.
2006
2nd Annual Meeting of the Oligonucleotide Therapeutics Society, New York, NY: Systemic delivery of siRNA via targeted nanoparticles. Heidel JD, Liu JY-C, and Davis ME. October 20, 2006.
231st National Meeting & Exposition, American Chemical Society, Atlanta, GA: Engineered polymers for targeted delivery of siRNA. Heidel JD and Davis ME. March 29, 2006.
2005
1st Annual Meeting of the Oligonucleotide Therapeutics Society, New York, NY: Targeted delivery of siRNA using a cyclodextrin polycation based system. Davis ME. September 16, 2005.
GTCBio RNAi Research and Therapeutics Conference, San Diego, CA: A polymeric, self-assembled system for the systemic administration of therapeutic siRNA. Heidel JD and Davis ME. December 1-2, 2005.
Pacifichem 2005: Systemic administration of siRNA against EWS-FLI1 using a targeted, non-viral formulation inhibits growth in a disseminated murine model of Ewing’s sarcoma. Davis ME, Heidel JD, Hu-Lieskovan S, Bartlett DW, and Triche TJ. December 19, 2005.
8th US-Japan Drug Delivery Symposium Lahaina, HI: Systemic delivery of short interfering RNA. Heidel JD, Liu J, Rossi JJ, and Davis ME. December 20, 2005.
NON-RNAi PAPERS & PRESENTATIONS
Papers
2009
Schluep, T., P. Gunawan, L. Ma, G. S. Jensen, J. Duringer, S. Hinton, W. Richter and J. Hwang (2009). "Polymeric Tubulysin-Peptide Nanoparticles with Potent Antitumor Activity." Clin Cancer Res 15(1): 181-189.
2008
Oliver, C. J., Y. Yen, T. Synold, T. Schluep and M. E. Davis (2008). "A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic, in refractory solid tumors." J Clin Oncol (Meeting Abstracts) 26 (May 20 suppl): 14538.
Jensen, G., J. Hwang and T. Schluep (2008). "Antitumor activity of IT-101, a cyclodextrin-containing polymer-camptothecin nanoparticle, in combination with various anticancer agents in human ovarian cancer xenografts." Proceedings of the 99th Annual Meeting of the American Association for Cancer Research: 767.
Hwang J, Rodgers K, Oliver CJ, Schluep T. (2008)“a-Methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy.” Int J Nanomedicine 3:359-71.
2006
Zeidan, R. K., S. A. Kalovidouris, T. Schluep, R. Fazio, R. Andresini and M. E. Davis (2006). "A Solvent-Free Method for Isotopically or Radioactively Labeling Cyclodextrins and Cyclodextrin-Containing Polymers." Bioconjug Chem. 17(6): 1624-1626.
Schluep, T., J. Cheng, K. T. Khin and M. E. Davis (2006). "Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice." Cancer Chemother Pharmacol. 57(5): 654-62. Epub 2005 Aug 26.
Schluep, T., J. Hwang, J. Cheng, J. D. Heidel, D. W. Bartlett, B. Hollister and M. E. Davis (2006). "Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models." Clin Cancer Res 12(5): 1606-1614.
2004
Cheng J, Khin KT, Davis ME (2004) Antitumor Activity of b-Cyclodextrin Polymer-Campthothecin Conjugates. Molecular Pharmaceutics 1: 183-193
Pun SH, Tack F, Bellocq NC, Cheng J, Grubbs BH, Jensen GS, Davis ME, Brewster M, Janicot M, Janssens B, Floren W, Bakker A (2004) Targeted Delivery of RNA-Cleaving DNA Enzyme (DNAzyme) to Tumor Tissue by Transferrin-Modified, Cyclodextrin-Based Particles. Cancer Biol Ther 3: 641-50. Epub 2004 Jul 09.
Pun SH, Bellocq NC, Liu A, Jensen G, Machemer T, Quijano E, Schluep T, Wen S, Engler H, Heidel J, Davis ME (2004) Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug Chem 15: 831-40.
Bellocq NC, Kang DW, Wang X, Jensen GS, Pun SH, Schluep T, Zepeda ML, Davis ME (2004) Synthetic Biocompatible Cyclodextrin-Based Constructs for Local Gene Delivery to Improve Cutaneous Wound Healing. Bioconjug Chem 15: 1201-1211.
2003
Cheng J, Khin KT, Jensen GS, Liu A and Davis ME (2003) Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem 14(5): 1007-17.
Bellocq NC, Pun SH, Jensen GS, Davis ME (2003) Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 14: 1122-32.
Bellocq NC, Davis ME, Engler H, Jensen GS, Liu A, Machemer T, Maneval D, Quijano E, Hwang SJ, Schluep T, Wen SF (2003) Transferrin-Targeted, Cyclodextrin Polycation-Based Gene Vector for Systemic Delivery. Mol Ther 7: S290
2002
Hwang Pun, S. and Davis, M.E. (2002) Development of a Nonviral Gene Delivery Vehicle for Systemic Application. Bioconjugate Chemistry 13: 630-639.
2001
Davis, M.E. (2001) Cyclodextrin-containing Polymers for Drug Delivery. PharmaTech, 185.
Hwang, S.J., Bellocq, N.C., and Davis, M.E. (2001) Effects of Structure of beta-cyclodextrin-containing Polymers on Gene Delivery. Bioconjugate Chemistry 12(2): 280-290.
Hwang, S.J., and Davis, M.E. (2001) Cationic Polymers for Gene Delivery: Designs for Overcoming Barriers to Systemic Administration. Current Opinion in Molecular Therapeutics 3(2): 183-191.
1999
Gonzalez, H., Hwang, S.J., and Davis, M.E. (1999) New Class of Polymers for the Delivery of Macromolecular Therapeutics. Bioconjugate Chemistry 10: 1068-1074.
Presentations
2007
American Society of Hematology Annual Meeting, Atlanta, GA: Preclinical Results of the Camptothecin-Polymer Conjugate IT-101 in Multiple Human Lymphoma Xenografts. Numbenjapon, T., J. Wang, D. Colcher, T. Schluep, M. E. Davis, J. Duringer, S. J. Forman and A. Raubitschek. December, 2007
AAPS Annual Meeting and Exposition, San Diego, California:. Enhanced Uptake of Cyclodextrin-Based Polymer Nanoparticles by Targeting with LHRH Peptide. Lim, C.-J., J. Hwang, P. Gunawan, M. E. Davis and T. Schluep. November, 2007
AAPS Annual Meeting and Exposition, San Diego, CA: Therapeutic evaluation of a-methylprednisolone conjugated polymer based nanoparticles for rheumatoid arthritis. Hwang, J., K. Rodgers and T. Schluep. November, 2007
American Society of Clinical Oncology (ASCO) 43rd Annual Meeting, Chicago Il: First-in-human phase I trial of a cyclodextrin-containing polymer-camptothecin nanoparticle in patients with solid tumors. Yen, Y., T. Synold, T. Schluep, J. Hwang, J. Oliver and M. E. Davis, July, 2007
American Association for Cancer Research Annual Meeting, Los Angeles, CA: (2007). Preclinical antitumor activity of polymer-tubulysin nanoparticles in human colorectal cancer xenograft. Gunawan, P., L. Ma, G. S. Jensen, W. Richter, A. Dömling, J. Hwang and T. Schluep. April, 2007. .
NSTI Nanotech 2007, Santa Clara, CA: Insert Therapeutics Product Development Update. Schluep, T. May, 2007.
2006
American Society of Hematology 48th Annual Meeting, Washington, DC: Preclinical Efficacy of Campthothecin-Polymer Conjugate (IT-101) in Human Burkitt Lymphoma Bearing Mice. Numbenjapon, T., J. Wang, D. Colcher, T. Schluep, S. J. Forman and A. Raubitschek. December, 2006.
XIII International Cyclodextrin Symposium, Torino, IT: Nanoparticulate chemotherapy with linear, cyclodextrin-containing polymers. Schluep, T. May, 2006.
2005
AACR meeting, Anaheim, CA: poster presentation: Camptothecin-polymer conjugate shows improved biodistribution and preclinical efficacy in vivo. Schluep T., Cheng J., Heidel J.D., Bartlett D.W., Hu S., Triche T.J., Davis M.E. April 2005
15th Annual Meeting and Exhibition of the Wound Healing Society, Chicago, Il, poster presentation: Synthetic, cyclodextrin-based polymer matrix for local regional drug delivery. Wound Repair Regen 13: A37. Schluep T, Bellocq NC, Jensen G, Davis ME . May, 2005
2004
14th Annual Meeting & Exhibition of the Wound Healing Society, Atlanta, GA: Cyclodextrin polymer based biocompatible matrix for local gene delivery. Kang DW, Bellocq NC, Schluep T, Looper LD, Gu DL, Quijano E, Wen SF, Coleman JA, Wang X, Jensen GS, Pun SH, Zepeda ML, Davis ME. May, 2004.
2003
CRS 30th Annual Meeting. Glasgow Scotland: Linear, water-soluble, cyclodextrin-containing polymers for the delivery of broad-ranging therapeutics. Davis, M.E., Heidel, J., Bellocq, N., Pun, S.H., Cheng, J., Dartt, C., Jensen, G., Khin, K., and Liu, A. July, 2003.
2002
Knowledge Foundation San Diego, CA: Gene Delivery: non-viral systems and in vivo applications. Bellocq, N.C., Davis, M.E., Engler, H., Jensen, G.S., Liu, A., Machemer, T., Maneval, D.C., Quijano, E., Pun, S.H., Schluep, T., and Wen, S. December, 2002
2nd International Symposium on Tumor Targeted Delivery Systems. Bellocq, N.C., Pun, S.H., Grubbs, B., Jensen, G.S., Liu, A., Cheng, J., and Davis, M.E. (2002)
Fifth Annual Meeting of The American Society of Gene Therapy: Synthesis and Studies of Chloroquine Analogues as Transfection Enhancing Agent for Non-Viral Delivery., abstract #681.Cheng, J., Liu A., Pun, S.H., Bellocq, N.C. and Davis, M.E. (2002)
Fifth Annual Meeting of The American Society of Gene Therapy: Cyclodextrin Polymer-based Gene Delivery Systems for Hepatocyte Targeting. abstract #669. Pun, S.H., Cheng, J., Bellocq, N.C., Jensen, G.S., and Davis, M.E. (2002)
AIChE National Meeting: Development of Stabilized Polymeric Particles for Targeted Gene Delivery. Pun, S.H., Jensen, G.S., Cheng, J., and Bellocq, N.C. (2002)
2001
American Chemical Society: Optimization of Cyclodextrin-containing Polymers Specifically Designed for Gene Delivery. abstract PMSE-0446 Bellocq, N., and Davis, M.E. Spring, 2001.
Keystone Conference: Gene Therapy: Design and Synthesis of Cyclodextrin-containing Polymers for Systemic Gene Delivery. abstract #14. Hwang, S.J., Bellocq, N., and Davis, M.E. (2001)
Fourth Annual Meeting of The American Society of Gene Therapy: A New Approach to PEGylation of Polyplexes for Stabilization Against Non-specific Interactions, abstract #1013.. Hwang, S.J., and Davis, M.E. (2001)
American Institute of Chemical Engineering Fall 2001 Meeting: A New Approach to the Stabilization of Polyplexes Against Non-Specific Interactions and the Targeted Delivery of Nucleic Acids, abstract #43e. Hwang, S.J., and Davis, M.E. (2001)
6th US-Japan Symposium On Drug Delivery Systems: Novel Gene Therapy Delivery Systems. Pun, S.H., Bellocq, N.C., and Davis, M.E. (2001) .
The Knowledge Foundation: Gene Delivery Systems – Improving Pathways, Efficiency and Stability: Cyclodextrin-based polymers for Targeted Delivery of Macromolecular Therapeutics. Pun, S.H. and Davis, M.E. (2001)
2000
Third Annual Meeting of The American Society of Gene Therapy: Design of Cyclodextrin-containing Polymers for Systemic Gene Delivery., abstract #306. Hwang, S.J., Bellocq, N., and Davis, M.E. (2000)
American Institute of Chemical Engineering Fall 2000 Meeting: Design of Cyclodextrin-containing Polymers for Systemic Gene Delivery, abstract #305g. Hwang, S.J., Bellocq, N., and Davis, M.E. (2000)
1999
Second Annual Meeting of The American Society of Gene Therapy: Synthetic, Cyclodextrin-Containing Polymers For Systemic Gene Delivery, abstract #928. Gonzalez, H., Hwang, S.J., and Davis, M.E. (1999)
Nature Biotechnology: Gene Therapy, Delivering the Medicines of the 21st Century: A New Class of Polymers for the Delivery of Macromolecular Therapeutics. Hwang, S.J., Gonzalez, H., and Davis, M.E. (1999)
Fifth US-Japan Symposium on Drug Delivery: A New Class of Polymers for the Delivery of Macromolecular Therapeutics. Hwang, S.J., Gonzalez, H., and Davis, M.E. (1999)
